Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas
详细信息 查看全文
- 作者：Susanne R. Teppera ; b ; susanne@seiwertlab.com" class="auth_mail" title="E-mail the corresponding author ; Zhixiang Zuoa ; zhixiang@seiwertlab.com" class="auth_mail" title="E-mail the corresponding author ; Arun Khattria ; arun@seiwertlab.com" class="auth_mail" title="E-mail the corresponding author ; Jochen Heß ; b ; c ; j.hess@dkfz-heidelberg.de" class="auth_mail" title="E-mail the corresponding author ; Tanguy Y. Seiwerta ; tseiwert@medicine.bsd.uchicago.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：EGFR ; epidermal growth factor receptor ; HNSCC ; head and neck squamous cell carcinoma ; RTK ; receptor tyrosine kinase ; CAFs ; cancer associated fibroblasts
- 刊名：Oral Oncology
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：56
- 期：Complete
- 页码：62-70
- 全文大小：1711 K
文摘
- •
Gefitinib treatment reduces viability in HN5, HN13, SCC61 and H400 HNSCC cell lines.
- •
AREG, HGF, TGFβ1, IGF1, FGF1 or FGF2 impair response of tumor cells to gefitinib.
- •
Gefitinib induces and growth factors diminish basal apoptosis in HNSCC tumor cells.
- •
Growth factor (GF) combinations have higher impact on viability than single GFs.
- •
Receptor expression indicates the extent of accordant ligands’ effect on viability.